Last reviewed · How we verify
Approved Hypertrophic Cardiomyopathy drug treatments
Approved Hypertrophic Cardiomyopathy drug treatments is a Calcium channel blocker Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 2 development for Hypertrophic cardiomyopathy.
Calcium channel blocker
Calcium channel blocker Used for Hypertrophic cardiomyopathy.
At a glance
| Generic name | Approved Hypertrophic Cardiomyopathy drug treatments |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Calcium channel blocker |
| Target | L-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Blocks L-type calcium channels in cardiac muscle cells, reducing contractility and heart rate.
Approved indications
- Hypertrophic cardiomyopathy
Common side effects
- Edema
- Dizziness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Approved Hypertrophic Cardiomyopathy drug treatments CI brief — competitive landscape report
- Approved Hypertrophic Cardiomyopathy drug treatments updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about Approved Hypertrophic Cardiomyopathy drug treatments
What is Approved Hypertrophic Cardiomyopathy drug treatments?
Approved Hypertrophic Cardiomyopathy drug treatments is a Calcium channel blocker drug developed by Bristol-Myers Squibb, indicated for Hypertrophic cardiomyopathy.
How does Approved Hypertrophic Cardiomyopathy drug treatments work?
Calcium channel blocker
What is Approved Hypertrophic Cardiomyopathy drug treatments used for?
Approved Hypertrophic Cardiomyopathy drug treatments is indicated for Hypertrophic cardiomyopathy.
Who makes Approved Hypertrophic Cardiomyopathy drug treatments?
Approved Hypertrophic Cardiomyopathy drug treatments is developed by Bristol-Myers Squibb (see full Bristol-Myers Squibb pipeline at /company/bristol-myers-squibb).
What drug class is Approved Hypertrophic Cardiomyopathy drug treatments in?
Approved Hypertrophic Cardiomyopathy drug treatments belongs to the Calcium channel blocker class. See all Calcium channel blocker drugs at /class/calcium-channel-blocker.
What development phase is Approved Hypertrophic Cardiomyopathy drug treatments in?
Approved Hypertrophic Cardiomyopathy drug treatments is in Phase 2.
What are the side effects of Approved Hypertrophic Cardiomyopathy drug treatments?
Common side effects of Approved Hypertrophic Cardiomyopathy drug treatments include Edema, Dizziness, Headache.
What does Approved Hypertrophic Cardiomyopathy drug treatments target?
Approved Hypertrophic Cardiomyopathy drug treatments targets L-type calcium channels and is a Calcium channel blocker.
Related
- Drug class: All Calcium channel blocker drugs
- Target: All drugs targeting L-type calcium channels
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertrophic cardiomyopathy